Charhon S A, Chavassieux P, Chapuy M C, Accominotti M, Traeger J, Meunier P J
Presse Med. 1986 Jan 18;15(2):55-9.
Three haemodialyzed chronic renal failure patients with histologically proven osteomalacia due to aluminium toxicity were treated with repeated injections of desferrioxamine, a potent chelator of aluminium. The drug, in doses of 3 or 6 g, was administered intravenously once a week for 5 to 11 months, at the end of a dialysis session. Treatment was well tolerated. Dramatic clinical improvement was observed, with rapid regression of pain and functional impairment. There was a 65% increase in alkaline phosphatase and a rise of immunoreactive parathyroid hormone (terminal C fragment). Healing of fractures was confirmed by radiology, and a second bone biopsy in the 3 patients after double tetracycline labelling showed regression of morphological and dynamic signs of osteomalacia, considerable reduction in stainable aluminium deposits and strong increase in bone remodelling compatible with the development of hyperparathyroidism. It is concluded that a moderate dose of desferrioxamine administered once a week is effective against osteomalacia due to aluminium toxicity.
三名经组织学证实因铝中毒导致骨软化症的慢性肾衰竭血液透析患者，接受了反复注射去铁胺（一种强效铝螯合剂）的治疗。该药剂量为3克或6克，在透析疗程结束时每周静脉注射一次，持续5至11个月。治疗耐受性良好。观察到临床症状显著改善，疼痛和功能障碍迅速消退。碱性磷酸酶增加了65%，免疫反应性甲状旁腺激素（C末端片段）升高。放射学检查证实骨折愈合，对这3名患者进行双重四环素标记后进行的第二次骨活检显示，骨软化症的形态学和动态体征消退，可染色铝沉积物显著减少，骨重塑显著增加，符合甲状旁腺功能亢进的发展。结论是，每周一次给予中等剂量的去铁胺对铝中毒所致骨软化症有效。
